Sign up to save your podcasts
Or
Share McKesson Corporation (MCK), 2024 Q4 earnings digest
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
McKesson Corporation (MCK), 2024 Q4 earnings digest
$MCK has released its fiscal Q4 earnings report. Key stats show a 12% revenue growth to $309 billion and adjusted EPS at $27.44 (+6%). Risks include increased operating expenses and a reserve for environmental matters. Highlights include a strong outlook for fiscal 2025 with anticipated revenue growth of 15%-17% 🚀.
Q4 saw revenues increase to $76.4 billion, with adjusted EPS at $6.18. Future opportunities lie in oncology and biopharma services, while risks include moderating GLP-1 medication growth 📉.
For further details, visit valueverge.com/MCK.
View all episodes
By ValueVerge$MCK has released its fiscal Q4 earnings report. Key stats show a 12% revenue growth to $309 billion and adjusted EPS at $27.44 (+6%). Risks include increased operating expenses and a reserve for environmental matters. Highlights include a strong outlook for fiscal 2025 with anticipated revenue growth of 15%-17% 🚀.
Q4 saw revenues increase to $76.4 billion, with adjusted EPS at $6.18. Future opportunities lie in oncology and biopharma services, while risks include moderating GLP-1 medication growth 📉.
For further details, visit valueverge.com/MCK.